ArticleFrontiers in cardiovascular medicine2025
The global burden of pediatric infective endocarditis (5-14 years): epidemiological patterns from 1990 to 2021 and projected trajectories.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric infective endocarditis (IE) remains a rare but life-threatening condition, with substantial morbidity and mortality among children worldwide. Despite advances in cardiac care and infection control, the global burden, temporal trends, and regional disparities of pediatric IE remain poorly characterized. Methods: We conducted a comprehensive analysis of pediatric IE burden among children aged 5-14 years using the Global Burden of Disease (GBD) 2021 dataset. Annual incidence, mortality, and disability-adjusted life years (DALYs) attributable to IE were estimated across 204 countries and territories from 1990 to 2021. Analyses were stratified by sex, region, and socio-demographic index (SDI). An autoregressive integrated moving average (ARIMA) model was applied to forecast pediatric IE trends through 2035. Results: Globally, the incidence of pediatric IE declined by 27.6% (95% UI, -30.9% to -24.9%) and mortality by 21.4% (95% UI, -35.2% to -0.8%) between 1990 and 2021, with an estimated annual percentage change (EAPC) of -1.37% (95% CI, -1.49% to -1.24%) and -0.64% (95% CI, -0.75% to -0.54%), respectively. DALYs decreased by 19.2% (95% UI, -33.2% to 1.9%). Marked disparities persisted, with high-SDI regions, notably China, achieving the greatest reductions in burden, while sub-Saharan Africa and Eastern Europe exhibited stagnant or increasing rates. The ARIMA model projected a potential stabilization or slight rebound in the global pediatric IE burden by 2035, particularly among girls, although wide confidence intervals highlight the uncertainty of long-term forecasts. Conclusions: While significant progress has been made in reducing the global burden of pediatric IE, major geographic and socio-demographic inequalities persist. Sustained efforts to strengthen early detection, risk stratification, prevention (including rheumatic heart disease control and antibiotic prophylaxis), and equitable access to cardiac care are urgently required-especially in low- and middle-income countries. Enhanced surveillance and data collection will be crucial to monitor trends, evaluate interventions, and achieve further reductions in pediatric IE morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.